KRAS and cancer: It is important to note that KRAS inhibition, when combined with RIG-I activation, can significantly elevate the formation of effector memory T cells in the CT26 tumor model, which exhibits a "hot tumor" profile characterized by highly infiltrated immune cells 42, Interestingly, even in the "cold" KP tumors, the Kras ASO and immRNA combination treatment partially increased the formation of effector memory T cells, suggesting that this approach may provide a durable anti-cancer effect.